| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From Ohio State University Hospitals, Columbus, OH; University of Minnesota Hospital, Minneapolis, MN; and the VA Hospital, Memphis, TN.
A controlled randomized trial of plasma exchange combined with prednisone was compared with supportive care alone in patients with Guillain-Barré syndrome (GBS). There was no significant improvement in the treated group over the controls. The sample size, albeit small (12 treated and 13 controls), had the power (95% chance) to detect a change of 2 British Medical Research Council grades of strength between the groups. The difference in our results and others that indicated a beneficial effect of plasma exchange may reflect an adverse effect of prednisone on recovery in GBS. Failure to find a benefit of plasma exchange in our patients also raises the possibility that GBS may be a heterogeneous disorder with humoral factors playing a role in some but not all patients.
Address correspondence and reprint requests to Dr. Mendell, Ohio State University, 466 West 10th Avenue, Columbus, OH 43210.
Accepted for publication March 7, 1985.
This article has been cited by other articles:
|
|
 |
|
  R. A. C. Hughes, A. V. Swan, J.-C. Raphael, D. Annane, R. van Koningsveld, and P. A. van Doorn Immunotherapy for Guillain-Barre syndrome: a systematic review Brain, September 1, 2007; 130(9): 2245 - 2257. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Natarajan and R. Weinstein Therapeutic Apheresis in Neurology Critical Care J Intensive Care Med, July 1, 2005; 20(4): 212 - 225. [Abstract] [PDF]
|
|
|
|
 |
|
 R.A.C. Hughes, E.F.M. Wijdicks, R. Barohn, E. Benson, D.R. Cornblath, A. F. Hahn, J.M. Meythaler, R.G. Miller, J.T. Sladky, and J.C. Stevens Practice parameter: Immunotherapy for Guillain-Barre syndrome: Report of the Quality Standards Subcommittee of the American Academy of Neurology Neurology, September 23, 2003; 61(6): 736 - 740. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Karussis and O. Abramsky Is the Routine Use of Intravenous Immunoglobulin Treatment in Neurologic Disorders Justified?: No Arch Neurol, August 1, 1999; 56(8): 1028 - 1032. [Full Text] [PDF]
|
|
|
|
 |
|
 H. R. Jones JR Topical Review: Childhood Guillain-Barre Syndrome: Clinical Presentation, Diagnosis, and Therapy J Child Neurol, January 1, 1996; 11(1): 4 - 12. [Abstract] [PDF]
|
|
|
|
|
|
R. J. Barohn, Z. Sahenk, J. R. Warmolts, and J. R. Mendell The Bruns-Garland Syndrome (Diabetic Amyotrophy) Revisited 100 Years Later Arch Neurol, November 1, 1991; 48(11): 1130 - 1135. [Abstract] [PDF]
|
|
|
|
|
|
F. J. Vriesendorp, R. F. Mayer, and C. L. Koski Kinetics of Anti-Peripheral Nerve Myelin Antibody in Patients With Guillain-Barre Syndrome Treated and Not Treated With Plasmapheresis Arch Neurol, August 1, 1991; 48(8): 858 - 861. [Abstract] [PDF]
|
|
|
|
|
|
R. J. Barohn, J. T. Kissel, J. R. Warmolts, and J. R. Mendell Chronic Inflammatory Demyelinating Polyradiculoneuropathy: Clinical Characteristics, Course, and Recommendations for Diagnostic Criteria Arch Neurol, August 1, 1989; 46(8): 878 - 884. [Abstract] [PDF]
|
|
|
|
|
|
S. J. Huber, J. T. Kissel, E. C. Shuttleworth, D. W. Chakeres, L. E. Clapp, and M. A. Brogan Magnetic Resonance Imaging and Clinical Correlates of Intellectual Impairment in Myotonic Dystrophy Arch Neurol, May 1, 1989; 46(5): 536 - 540. [Abstract] [PDF]
|
|
|
|
|
|
G. Gruener, E. P. Bosch, R. G. Strauss, M. Klugman, and J. Kimura Prediction of Early Beneficial Response to Plasma Exchange in Guillain-Barre Syndrome Arch Neurol, March 1, 1987; 44(3): 295 - 298. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
